| First Author | Giannopoulos PF | Year | 2013 |
| Journal | Biol Psychiatry | Volume | 74 |
| Issue | 5 | Pages | 348-56 |
| PubMed ID | 23683389 | Mgi Jnum | J:284655 |
| Mgi Id | MGI:6385997 | Doi | 10.1016/j.biopsych.2013.04.009 |
| Citation | Giannopoulos PF, et al. (2013) 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biol Psychiatry 74(5):348-56 |
| abstractText | BACKGROUND: 5-lipoxygenase activating protein (FLAP) is abundantly present in the central nervous system. Although its function has been extensively interrogated in the context of peripheral inflammation, novel roles for this protein are emerging in the central nervous system. The objective of our study was to investigate the functional role that FLAP plays in a mouse model of Alzheimer's disease (AD) with plaques and tangles (i.e., 3xTg mice). METHODS: By implementing a genetic knockout of FLAP and pharmacologic inhibition with a FLAP inhibitor (MK-591), we evaluated the effect on the AD-like neuropathology, cognition, and synaptic plasticity in the 3xTg mice. RESULTS: We show that reduction of FLAP leads to amelioration of cognition and memory along with the rescuing of synaptic dysfunction at an early age before the development of overt neuropathology. Genetic knockout and pharmacologic inhibition of FLAP also yielded an improvement in AD pathology through a reduction in Abeta via the gamma-secretase pathway and a decrease in tau phosphorylation through the cdk5 pathway. CONCLUSIONS: Our studies identify a novel functional role for FLAP in regulating memory and synaptic plasticity. They establish this protein at the crossroad of multiple pathways that ultimately contribute to the development of the entire AD-like phenotype, making it a viable therapeutic target with disease-modifying capacity for the treatment of this disease. |
